

ORAL PRESENTATION

Open Access

Identifying dominant modifiers of mutant FUS toxicity *in vivo*

J Gavin Daigle¹, Nicholas A Lanson¹, Ian Casci¹, John Monaghan¹, Charles Nichols², Dimitri Kryndushkin³, Frank Shewmaker³, Udai Pandey^{1*}

From Molecular Neurodegeneration: Basic biology and disease pathways Cannes, France. 10-12 September 2013

FUS is a DNA/RNA binding protein found to be mutated in some cases of both sporadic and familial forms of ALS. It is still not clear how ALS-causing mutations in FUS leads to motor neuron degeneration. Here, we exploited a Drosophila model and mammalian neuronal cell lines to elucidate the role of the RNA-binding ability of FUS in regulating FUS-mediated toxicity. To determine the role of the RNA binding ability of FUS in ALS, we mutated FUS RNA binding sites (F305, F341, F359, F368) to leucines and generated RNA binding-incompetent mutants (4F-L) with and without ALS causing mutations R518K or R521C. We found that mutating 4F to L residues makes FUS RNA binding-incompetent. We observed that ectopic expression of RNA binding-incompetent FUS in fly brain, eyes and motor neurons strongly blocks neurodegenerative phenotypes as compared to RNAbinding-competent FUS carrying ALS causing mutations. Interestingly, RNA-binding deficient FUS strongly localized to the nucleus of Drosophila motor neurons and mammalian neuronal cells whereas FUS carrying ALS linked mutations was distributed to the nucleus and cytoplasm.

Importantly, we found that incorporation of mutant FUS into stress granules is dependent on the RNA-binding ability of FUS. SGs are dynamic aggregates composed of proteins and RNA that are formed when cells are under a variety of stresses. We observed that normally cytoplasmic SGs rapidly disassemble when stress conditions end, whereas cytoplasmic SGs formed in ALS patient cells having a FUS mutation fail to disassemble. This suggests that mutant FUS sequesters proteins and RNAs important for cellular homeostasis and the defect in disassembly of cytoplasmic SGs contributes to ALS. Finally, following up

these observations we performed an *in vivo* unbiased genetic screen that led to the discovery of several dominant modifiers of mutant FUS toxicity including proteins involved in regulating SG dynamics, mitochondrial functions and RNA splicing. These genetic modifiers would help in identifying potential therapeutic targets for ALS.

Authors' details

¹Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA. ²Department of Pharmacology and Experiment Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, USA. ³Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Published: 13 September 2013

doi:10.1186/1750-1326-8-S1-O33

Cite this article as: Daigle *et al.*: Identifying dominant modifiers of mutant FUS toxicity *in vivo*. *Molecular Neurodegeneration* 2013 **8**(Suppl 1):

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



Full list of author information is available at the end of the article



¹Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA